NASDAQ:JAGX Jaguar Animal Health Q2 2026 Earnings Report $3.95 -0.55 (-12.22%) Closing price 10/1/2026 04:00 PM EasternExtended Trading$3.88 -0.08 (-1.90%) As of 10/1/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Jaguar Animal Health EPS ResultsActual EPS-$15.70Consensus EPS -$782.25Beat/MissBeat by +$766.55One Year Ago EPSN/AJaguar Animal Health Revenue ResultsActual Revenue$1.23 millionExpected Revenue$4.24 millionBeat/MissMissed by -$3.02 millionYoY Revenue GrowthN/AJaguar Animal Health Announcement DetailsQuarterQ2 2026Date8/19/2026TimeAfter Market ClosesConference Call DateWednesday, August 19, 2026Conference Call Time7:00AM ETUpcoming EarningsJaguar Animal Health's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Jaguar Animal Health Earnings HeadlinesAnalyzing Jaguar Animal Health (NASDAQ:JAGX) and Spero Therapeutics (NASDAQ:SPRO)September 30 at 4:45 AM | americanbankingnews.comJaguar Health (JAGX)September 25, 2026 | es.investing.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. | Stansberry Research (Ad)Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split FloatSeptember 25, 2026 | 247wallst.comJaguar Health Stock Slides Thursday: What's Happening?September 24, 2026 | benzinga.comViking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%September 24, 2026 | 247wallst.comSee More Jaguar Animal Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jaguar Animal Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jaguar Animal Health and other key companies, straight to your email. Email Address About Jaguar Animal HealthJaguar Animal Health (NASDAQ:JAGX) is a biopharmaceutical company focused on developing and commercializing medicines and health products for animals. The company’s research is centered on naturally derived compounds, particularly plant-based products designed to address gastrointestinal disorders and other health conditions in companion and production animals. Jaguar’s portfolio and development programs include products for dogs, cats, horses and livestock. Its best-known product is Canalevia-CA1, a crofelemer-based prescription product that received conditional approval from the U.S. Food and Drug Administration for the management of chemotherapy-induced diarrhea in dogs. The company has also developed supportive-care products for young animals, including Neonorm products intended to help manage gastrointestinal health in calves, foals, puppies and kittens. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar’s operations include research and development, regulatory activities and the commercialization of animal-health products through its own efforts and commercial relationships. Lisa Conte, who founded Jaguar, serves as its president and chief executive officer. The company’s products and programs are primarily directed at the U.S. veterinary market, with international opportunities pursued through partnerships and distribution arrangements.View Jaguar Animal Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
